Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-operative adjuvant nivolumab with concomitant chemoradiotherapy in high-risk resected SCCHN
2024-513206-65-00Phase 3Authorised
- Sponsor
- GORTEC
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Disease-free survival (DFS) by investigator imaging assessments. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-513206-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513206-65-00.